Table 1 Clinicopathological characteristics of the patients’ sample.
|  | Matched breast cancer samples (n = 55) | |
|---|---|---|
Breast cancer subtype | IDC | 48 (87%) |
ILC | 3 (6%) | |
Other | 4 (7%) | |
Stage | Stage I | 25 (45%) |
Stage II | 16 (29%) | |
Stage III | 14 (26%) | |
Grade | Grade 1 | 1 (2%) |
Grade 2 | 25 (45%) | |
Grade 3 | 29 (53%) | |
Lymphovascular invasion | Present | 27 (49%) |
Not identified | 28 (51%) | |
Lymph node involvement | Positive | 34 (62%) |
Negative | 21 (38%) | |
Luminal A | ER + /PR + /HER2 - | 34 (64%) |
Luminal B | ER + /PR + /HER2 +  | 15 (27%) |
HER2 +  | ER-/PR- & HER +  | 4 (7%) |
TNBC | ER-/PR-/HER2- | 2 (4%) |
ER | Positive | 44 (80%) |
Negative | 11 (20%) | |
PR | Positive | 37 (67%) |
Negative | 18 (33%) | |
HER2 | Positive | 19 (34%) |
Negative | 36 (66%) | |
